Full-Time

Associate Director

Medical Education and External Research

Posted on 8/19/2025

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Biopharmaceutical company developing CNS therapies

Compensation Overview

$155k - $185k/yr

+ Bonus + Equity

New York, NY, USA

In Person

On-site requirement of at least three days per week.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Bachelor’s degree required, preferably in a health-related field. Master’s degree or higher preferred (PharmD, PhD)
  • 7+ years of relevant experience within the Pharma/Biotech industry
  • Demonstrated understanding of the legal and regulatory guidelines (e.g., PhRMA, ACCME, Sunshine Act, etc.) associated with independent medical education, pharmaceutical industry research, and external granting functions and the ability to use knowledge to make sound operational decisions
  • Knowledge of CME/CE outcomes assessment models (e.g., Moore’s levels)
  • Occasional travel (up to 20%) for conferences and meetings
  • Ability to work on site Monday, Tuesday & Thursday. We are unable to consider candidates who are looking for fully remote roles.
Responsibilities
  • In collaboration with Medical Affairs colleagues, develop and implement medical education and external research/IST objectives and annual plans for all Axsome therapeutic areas
  • Lead and work cross functionally with internal and external colleagues, including legal, compliance, finance, accounts payable, Regional Medical Affairs, etc
  • Contribute to the development and refinement of the IME and external research/IST framework and SOPs to ensure a robust and compliant process for review and management of IME programs and external research studies
  • Manage and evaluate all incoming IME grant requests and external research/IST proposals and assess for appropriateness and compliance with Axsome criteria, policies and procedures
  • Lead development and implementation of the Educational Grant Review Committee and External Research Collaborations Committee structures
  • Lead internal review committee meetings for the endorsement and approval of IME programs and management of external research/IST studies
  • Lead negotiation of education and research agreements and statements of work (including changes of scope where applicable)
  • Manage reconciliation process of all medical education providers in collaboration with compliance team to ensure timely reporting per Sunshine Act
  • Provide operational support for external research studies, including oversight of contract compliance, management of payments, provision of drug supply, and management of study progress reports
  • Manage educational grant and external research budgets across all therapeutic areas and report accruals to accounting according to the financial schedules
  • Manage all financial and contractual aspects of assigned projects, including vendor relationships
  • Lead operational efficiencies and enhancing day-to-day practices and processes for optimal decision making and collaboration across the IME and external research functions including timely achievement of short to long term deliverables
  • Liaise with internal and external stakeholders to ensure timely communication of approved IME and research activities, study progress, and delays
  • Maintain current knowledge of relevant information sources and key continuing medical education and external research landscape events which may impact IME and/or external research policies and procedure
  • Participate in training and understand policies from Axsome compliance to ensure supported educational programs and research activities are consistent with guidelines (e.g., ACCME, PhRMA, EACME, OIG, FDA)
  • Maintain and manage educational and research information on the Axsome Medical Affairs website
  • In collaboration with Scientific Affairs Team Leadership, create function and project-specific dashboards and develop KPIs/metrics for each function. Lead operational excellence initiatives for the Scientific Affairs Team.
Desired Qualifications
  • CNS experience preferred
  • Knowledge of instructional design principles as they pertain to IME is preferred
  • Professional certification in medical education (e.g., CHCP) preferred
  • Experience with educational grant and research management systems (e.g., CyberGrants)
  • Experience working with spreadsheets (e.g., Excel, Smartsheets)
  • Data analytics and dashboard creation using visualization software (e.g., Power BI) is desired
  • Experience managing vendors
  • Excellent verbal and written communication skills
  • Demonstrated expertise in development and execution of medical education strategies is desired
  • Proven skills in negotiation, influencing without authority, managing through ambiguity, and working diplomatically through conflict
  • Flexible and able to work independently in a fast-paced, rapidly changing environment on multiple projects efficiently
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders and focuses on research, development, and commercialization of medicines. Its lead product candidate, AXS-05, is an oral NMDA receptor antagonist being developed to treat major depressive disorder (MDD) and treatment-resistant depression (TRD). The company moves its pipeline through clinical trials and regulatory approvals to bring therapies to patients and earns revenue from drug sales, partnerships, and licensing. It differentiates itself by pursuing CNS-focused therapies with NMDA receptor targets and by pursuing designations like FDA Breakthrough Therapy to speed development, with a goal of improving patient outcomes and quality of life.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Auvelity Q1 2026 revenue hit $153.2M, up 59%, with $8B peak sales outlook post-Alzheimer's approval.
  • Total Q1 2026 revenue reached $191M, up 57%, beating estimates via sales force expansion.
  • Pipeline advances with AXS-12 NDA submission and AXS-20 addition for schizophrenia.

What critics are saying

  • Symbravo loses share to generic triptans and gepants due to high FDC pricing in 6-12 months.
  • AXS-12 NDA fails FDA approval from weak Phase III data, dropping stock 30-50% in 12-18 months.
  • Cash burns $305M reserves from sales force doubling before profitability in 18-24 months.

What makes Axsome Therapeutics Inc unique

  • Auvelity targets NMDA receptors for MDD and Alzheimer's agitation with FDA approvals.
  • Symbravo combines meloxicam-rizatriptan for acute migraine with long-term MOVEMENT trial benefits.
  • Sunosi treats narcolepsy daytime sleepiness with expanding Phase 3 indications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Yahoo Finance
Apr 8th, 2026
Axsome Therapeutics surges 33% annually since 2015 IPO, eyes $16B peak sales

Axsome Therapeutics, a midcap biotech, has delivered a compound annual growth rate of 33.32% since its 2015 IPO, potentially turning a $50,000 investment into nearly $1 million. However, replicating this performance over the next decade would require the company to reach a market capitalisation of approximately $157 billion. The company's 2025 revenue grew 66% year over year to $638.5 million, driven primarily by Auvelity, a depression treatment. Auvelity may soon receive approval for treating agitation in Alzheimer's disease, expanding its addressable market to over five million US patients. Axsome Therapeutics' pipeline includes several phase 3 assets targeting over 150 million patients, with predicted peak sales exceeding $16 billion. Whilst the company shows promise for long-term growth through the 2040s, matching its historical performance remains unlikely.

Bitget
Mar 18th, 2026
Superstring Capital invests $6.84M in CNS pharma Axsome Therapeutics, stock up 27%

Superstring Capital Management invested $6.84 million in Axsome Therapeutics, purchasing 37,433 shares during Q4 2025, according to a SEC filing dated 17 February 2026. The investment represents nearly 4% of the fund's reported 13F assets. Axsome Therapeutics, a clinical-stage biopharmaceutical company, develops treatments for central nervous system conditions including major depressive disorder, migraines and narcolepsy. The company has commercialised several treatments and recently launched a Phase 3 trial for solriamfetol in major depressive disorder with excessive daytime sleepiness. Axsome shares traded at $158.40 on Wednesday, up 27% over the past year, outpacing the S&P 500's 19% gain. The company reported $638.5 million in annual revenue, a 66% increase from 2024, with a market capitalisation of $8.1 billion.

Yahoo Finance
Mar 18th, 2026
Superstring Capital bets $6.8M on CNS drugmaker Axsome as Phase 3 trial begins and shares climb 27%

Superstring Capital Management has disclosed a new $6.84 million position in Axsome Therapeutics, acquiring 37,433 shares during the fourth quarter of 2025. The stake represents nearly 4% of the fund's assets under management. Axsome Therapeutics, a biopharmaceutical company specialising in central nervous system disorder treatments, has seen its shares rise 27% over the past year to $158.40. The company generated $638.5 million in revenue over the trailing twelve months, representing 66% growth from 2024. The company markets therapies for depression, migraine and sleep disorders whilst advancing a late-stage pipeline. Axsome recently initiated a Phase 3 trial for solriamfetol targeting major depressive disorder with excessive daytime sleepiness, a segment with no approved treatments currently available.

Yahoo Finance
Mar 12th, 2026
Axsome's Auvelity surpasses $500M revenue, eyes approval for Alzheimer's agitation by April

Axsome Therapeutics reported Auvelity surpassed $500 million in revenue during its third year, with total company sales approaching $640 million in 2025. Auvelity posted approximately 68% year-over-year growth. The company's supplemental NDA for AXS-05 (Auvelity) in Alzheimer's disease agitation is under priority review, with a PDUFA date of 30 April 2026. This represents Axsome's key near-term regulatory catalyst, supported by three positive trials. Axsome is doubling its field force from 300 to 600 representatives by Q2, ahead of a potential launch. The company is advancing seven Phase III trials across multiple indications whilst maintaining approximately $323 million in cash to fund operations.

Yahoo Finance
Mar 6th, 2026
Axsome doubles salesforce to 600 reps as AUVELITY hits $155M quarter ahead of April Alzheimer's decision

Axsome Therapeutics reported $155 million in quarterly revenue for AUVELITY, annualising over $600 million just 13 quarters post-launch, though market penetration remains at approximately 0.2% of the antidepressant market. The company plans to double its salesforce from 300 to 600 representatives to drive uptake and support a potential Alzheimer's agitation launch. Over 50% of AUVELITY prescriptions are now monotherapy, with roughly 15% first-line and 35% first-switch therapy. Primary care clinicians account for about 30% of prescribers. Axsome's supplemental NDA for AXS-05 in Alzheimer's disease agitation is under priority review with an FDA decision expected on 30 April. Management reported revenue growth outpacing operating expenses by 3-to-1 in 2025, demonstrating strong operating leverage despite increased direct-to-consumer spending.

INACTIVE